9Bio Therapeutics honored with DEVTECH award by Québec International and Québec VITAE
Quebec City, January 28, 2025 – 9Bio Therapeutics is proud to announce its recognition at this year’s DEVTECH Life Sciences and Health Technologies Entrepreneurial Competition. This award, presented by Québec International and Québec VITAE, acknowledges the potential of 9Bio’s team and platform technology to develop conditionally active therapies targeting the tumor microenvironment.
As a result, we will receive support to present our most recent achievements at two pivotal biotech industry events in Boston: Redefining Early Stage Investments (RESI) 2025 conference and BIO International Convention 2025. These events will provide valuable opportunities to engage with investors and industry partners, fostering new collaborations within the international biotech community.
Celebrating Innovation in Life Sciences
The DEVTECH competition spotlights emerging startups that are shaping the future of life sciences. Previous awardees included Feldan Therapeutics, Omy Labs, Saguaro, Zilia, Syneos, and GSK. Alongside 9Bio Therapeutics, other awardees from this year include:
- Nanofacile (Ruben Lopez): Accelerating the development of targeted RNA therapies.
- EncephalX (Simon Lapointe): Innovating in neurosurgical instruments.
We extend our heartfelt congratulations to these innovators and express our gratitude to the organizers, jury members, and event partners, including Lumira Ventures, adMare BioInnovations, Axelys, BIOQuébec, and the Conseil de l’innovation du Québec.
DEVTECH: A Platform for Future Growth
Since its inception in 2012, the DEVTECH competition has been instrumental in stimulating, training, promoting, and supporting emerging companies in the life sciences and health technologies sector across Québec. This year’s edition featured a panel of investors and serial entrepreneurs, providing participants with a unique opportunity to showcase their business projects and connect with a network of experts and strategic partners.
“We are honored to be a recipient of this year’s DEVTECH award. This recognition reinforces our commitment to innovating precision therapies for cancer patients.” said Philipe Gobeil, President and Chief Scientific Officer of 9Bio Therapeutics.
About 9Bio Therapeutics
9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes three discovery-stage therapies: an antibody-drug conjugate (ADC) targeting tumor cells, an ADC targeting tumor-subverted immune cells, and an engineered cytokine.